Demographic characteristics of SJS and sicca patients
| Variable | Whole cohort | Proteomic cohort | ||
| SjS (n=172) | Sicca (n=145) | SjS (n=53) | Sicca (n=60) | |
| Age (years) | 58.5±15 | 56.1±12.8 | 55±13 | 60±12 |
| Sex | 162 F 10 M | 126 F 19 M | 50 F 3 M | 54 F 6 M |
| Anti-Ro positivity n (%) | 149 (87) | 0 | 41 (77) | 0 |
| Symptom duration ((years, median, (IQR)) | 8(8.7) | 8.2 (7.5) | 6 (6) | 9 (7) |
| Schirmer’s test (mm) | 6.7±9 | 12.5±12 | 9±10 | 15±13 |
| Unstimulated salivary flow (mL/5 min) | 0.53±0.8 | 0.9±1.2 | 0.5±0.6 | 0.8±1.2 |
| Stimulated salivary flow (mL/5 min) | 2.7±3.1 | 3.8±4.5 | 2.7±3 | 3±3 |
| ESSDAI (1–7) | 4.8±5.5 | N/A | 4.5±4 | N/A |
| ESSDAI domains n (%) | ||||
| Constitutional | 31 (18) | 12 (23) | ||
| Lymphadenopathy | 10 (6) | 2 (4) | ||
| Glandular | 46 (27) | 10 (19) | ||
| Articular | 54 (31.4) | 18 (34) | ||
| Muscular | 1 (0.6) | 1 (2) | ||
| Cutaneous | 7 (4) | 2 (4) | ||
| Respiratory | 15 (8.7) | 5 (9.4) | ||
| Neurological | 9 (5.2) | 2 (4) | ||
| Haematological | 37 (21.5) | 9 (17) | ||
| Biological | 91 (53) | 25 (47) | ||
| Renal | 7 (4) | 1 (2) | ||
| ESSPRI (0–10) | 6±2 | 6.2±2.2 | 6±2.2 | 5.9±1.8 |
| Focus score (<1) | 1.7±0.8 | N/A | 1.6±1 | N/A |
| IgG (g/L) (6-16) | 17.5±9 | 11.2±3 | 16.5±7.8 | 10±2 |
| CRP (mg/L) (0–3) | 2.5±4.8 | 3.1±5.3 | 3.3±6.3 | 2±4 |
| RF positivity n (%) | 106 (62) | 11 (7.6) | 33 (62) | 8 (13) |
| C3 (g/L) (0.75–1.65) C4 (g/L) (0.14–0.54) | 1.3±0.3 0.3±0.3 | 1.4±0.2 0.2±0.1 | 1.4±0.2 0.2±0.1 | 1.3±0.2 0.3±0.1 |
| Serum free light chain (K/L) quotient (0.26–1.65) | 1.1±0.8 | 0.9±0.5 | 1.3±0.5 | 0.9±0.4 |
| Hb1Ac (mmol/mol) (42-47) | 39.2±8 | 39.2±9.7 | 39±10 | 37±6 |
| BMI (kg/m2) (18.5–24.9) | 27.5±5.6 | 28.7±6.4 | 28.6±6.5 | 28±5.8 |
| Fibromyalgia diagnosis n (%) | 15 (8.7) | 29 (20) | 5 (9.4) | 9 (15) |
| Type 2 diabetes diagnosis n (%) | 10 (5.8) | 14 (9.6) | 5 (9.4) | 5 (8.3) |
| OSDI | 42±26 | 47.2±26.5 | 38±23.4 | 45±24 |
| Anxiety (HADS-A) | 8.5±4.5 | 8.2±4.3 | 9.8±5 | 8.8±4.2 |
| Depression (HADS-D) | 7.4±4 | 6.9±4 | 8±4.4 | 6.6±4 |
| EQ5D utility value (UK) | 0.6±0.3 | 0.6±0.3 | 0.6±0.4 | 0.6±0.3 |
| EQ5D VAS (patient) | 61±20 | 58±22 | 59±22 | 60±20 |
| Treatment n, (%) | 52 (30) (46 HQ, 5 MTX, 2 AZA, 7 CCS, 1 MMF) | 19 (13) (14 HQ, 3 MTX, 2 AZA, 3 CCS) | 13 (25) (10 HQ, 1 MTX, 1 AZA, 2 CCS) | 6 (10) (5 HQ, 2 MTX, 3 CCS) |
Values are expressed as mean (SD) unless specified.
Normal ranges for some of the parameters are indicated in the brackets.
.AZA, azathioprine; BMI, body mass index; C3, Complement component 3; C4, Complement component 4; CCS, corticosteroids; CRP, C reactive protein; EQ5D, EuroQoL-5 Dimension; ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren’s Syndrome Patient-Reported Index; HADS, Hospital Anxiety and Depression Scale; HQ, hydroxychloroquine; K/L, kappa/lambda serum free chain ratio; MMF, mycophenolate mofetil; MTX, methotrexate; n, number of patients; N/A, not applicable; OSDI, Ocular Surface Disease Index; RF, rheumatoid factor; SjS, Sjogren’s syndrome; VAS, Visual Analogue Scale.